Topcon Healthcare acquires RetInSight to fuel AI in retinal disease diagnosis, monitoring

Topcon Healthcare announced it is acquiring RetInSight, a technology company that provides retinal imaging and AI algorithms that enable automated analysis of retinal images. The financial terms of the deal were not disclosed in the press release.

“RetInSight’s OCT-based AI expertise will help our global network of partners rapidly deploy innovations,” Ali Tafreshi, CEO and president of Topcon Healthcare, said in a press release. “Integrated with our Harmony vendor-inclusive digital information system, we’re delivering clinical decision support and a scalable ecosystem for AI deployment.”

Topcon Healthcare has long operated under the vision of “Healthcare from the Eye,” which ties in with RetInSIght’s AI algorithms that analyze optical coherence tomography (OCT) images to detect and monitor retinal diseases, such as geographic atrophy, neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. These retinal diseases are the leading causes of vision loss globally, and an AI tool that can flag warning signs on an OCT image taken during a routine exam may help eye care providers diagnose and begin intervention earlier.

"RetInSight’s innovative AI capabilities align perfectly with our vision to expand access to intelligent diagnostic tools that support early detection, personalized care, and population health management," Fumio Ohue, senior vice president and chairman of Topcon Healthcare, said in a news release. "This acquisition enhances our ability to deliver high-quality, accessible eye care while also reducing costs and improving clinical outcomes on a global scale."

Topcon and RetInSight entered a partnership in 2021 to combine forces of RetInSight’s AI application and Topcon’s OCT devices and cloud-based data management platform Harmony. The evolution of partnership into acquisition supports Topcon’s vision of “Healthcare from the Eye,” as they hope intelligent diagnostics will increase access to high-quality eye care.

“With Topcon Healthcare’s infrastructure, we can scale reliable and affordable AI software globally,” Prof. Hans Peter Schwarz, Chairman of the Board of RetInSight, said in a press release. “This partnership supports clinical care, drug discovery, and therapeutic innovation worldwide.”

RetInSight’s platform was created at the Medical University of Vienna, in the department of ophthalmology and optometry, under the direction of Prof. Dr. Ursula Schmidt-Erfurth. The system is already commercialized in Europe and supports multiple OCT systems, regardless of vendor. The algorithms have also been used in pharmaceutical trials to support AI-powered drug development and regulatory pathways. It has also been used to advance FDA clearances for US indications.

“Together, we’re enabling seamless patient monitoring across the eye care continuum,” said Dr. Amir Sadeghipour, Managing Director of RetInSight. “This collaboration brings intelligent care to patients anywhere.”

Reference

Topcon Healthcare, Inc. Acquires RetInSight GmbH to Accelerate its AI-Powered Imaging Innovation in Eye Care. Topcon Healthcare. Press release. Published May 2, 2025. Accessed May 2, 2025. https://topconhealthcare.com/article/topcon-healthcare-inc-acquires-retinsight-gmbh-to-accelerate-its-ai-powered-imaging-innovation-in-eye-care/